Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning-Derived Diverse Regulated Cell Death Patterns for Therapeutic Target Identification in Glaucoma.

International journal of general medicine·2025
Same author

Lycium Barbarum Polysaccharide-Derived Nanoparticles Protect Visual Function by Inhibiting RGC Ferroptosis and Microglial Activation in Retinal Ischemia‒Reperfusion Mice.

Advanced healthcare materials·2024
Same author

The ubiquitin ligase STUB1 suppresses tumorigenesis of renal cell carcinomas through regulating YTHDF1 stability.

Carcinogenesis·2024
Same author

Oxidative stress and epigenetics in ocular vascular aging: an updated review.

Molecular medicine (Cambridge, Mass.)·2023
Same author

m6A Modification-Association with Oxidative Stress and Implications on Eye Diseases.

Antioxidants (Basel, Switzerland)·2023
Same author

Endothelial deletion of TBK1 contributes to BRB dysfunction via CXCR4 phosphorylation suppression.

Cell death discovery·2022

Related Experiment Video

Updated: Jun 4, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

ROS-pH Dual-Responsive Polydopamine Nanoparticles for Targeted Fasudil Delivery Ameliorate Multiple Pathologies in

Jiaqi Li1, Zheng Zhong1, Yuhe Tan1

  • 1Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Otolaryngologic and Ophthalmic Diseases, Wuhan, 430068, People's Republic of China.

International Journal of Nanomedicine
|June 3, 2026
PubMed
Summary

This study developed a dual-responsive nanoplatform for diabetic retinopathy (DR) treatment, combining sustained ROCK inhibition with antioxidant activity to improve ocular retention and target multiple pathways.

Keywords:
ROCK inhibitioncombination therapydiabetic retinopathypH-responsivepolydopamine nanoparticlesreactive oxygen species

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Related Experiment Videos

Last Updated: Jun 4, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Area of Science:

  • Ophthalmology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Diabetic retinopathy (DR) pathogenesis involves oxidative stress and Rho-associated kinase (ROCK) signaling.
  • Current anti-VEGF therapies have limited efficacy due to failure to address these pathways.
  • Fasudil, a ROCK inhibitor, shows promise but faces challenges in ocular delivery and specificity.

Purpose of the Study:

  • To engineer a novel nanoplatform for sustained and targeted delivery of Fasudil in DR.
  • To develop a system with dual responsiveness to reactive oxygen species (ROS) and pH.
  • To combine ROCK inhibition with antioxidant properties for a multi-faceted therapeutic approach.

Main Methods:

  • Engineered a polydopamine nanoplatform (Fasudil@PDA) responsive to ROS and pH.
  • Achieved high drug loading (~28%) and characterized sustained Fasudil release in vitro (87.3% over 56 days).
  • Evaluated ROS scavenging, endothelial barrier restoration, and in vivo efficacy in choroidal neovascularization and diabetic mouse models.

Main Results:

  • Fasudil@PDA demonstrated sustained drug release in response to DR-associated ROS and acidic pH.
  • The nanoplatform effectively neutralized ROS and restored endothelial barrier integrity by inhibiting the ROCK/MLC pathway.
  • In vivo studies showed suppressed angiogenesis, reduced vascular leakage, neuroinflammation, and restored retinal function in diabetic mice.

Conclusions:

  • Developed a multi-faceted nanotherapeutic strategy combining sustained ROCK inhibition and antioxidant activity.
  • The nanoplatform is activated by DR pathological cues (pH, ROS), precisely targeting multiple pathways.
  • This approach offers a promising and translatable paradigm to overcome limitations of current DR monotherapies.